New Immunotherapy Increases Brain Cancer Patient Survival Time – AJMC.com Managed Markets Network
|
New Immunotherapy Increases Brain Cancer Patient Survival Time
AJMC.com Managed Markets Network Tocagen, a cancer-selective gene therapy company, is developing a new immunotherapy for patients with recurrent brain cancer called Toca 511 and Toca FC, referred to as the “Toca regimen.” The investigational products are currently being evaluated in a … |
